Latest On Acorda Therapeutics, Inc (ACOR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 05:46 EST | News | Acorda Therapeutics GAAP EPS of -$0.69 beats by $0.42, revenue of $22.25M misses by $8.76M | N/A |  |
| 2023-05-12 05:45 EST | News | Acorda Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation | N/A | |
| 2023-05-12 05:45 EST | News | Acorda Therapeutics, Inc. (ACOR) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-11 01:30 EST | News | Acorda Therapeutics Q1 Earnings Preview | N/A | |
| 2023-05-10 12:16 EST | News | Acorda Therapeutics down 8%, makes $6.2M interest payment in cash | N/A | |
About Acorda Therapeutics, Inc (ACOR):
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license read more...agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
General
- Name Acorda Therapeutics, Inc
- Symbol ACOR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:6
- Last Split Date2021-01-04
- Fiscal Year EndDecember
- IPO Date2006-02-10
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.acorda.com
Valuation
- Trailing PE 1.11
- Price/Sales (Trailing 12 Mt.) 0.32
- Price/Book (Most Recent Quarter) 0.24
- Enterprise Value Revenue 1.66
- Enterprise Value EBITDA 2.21
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$7.54
- Next Year EPS Estimate -$4.59
- Next Quarter EPS Estimate -$2.37
- Profit Margin -65%
- Operating Margin -57%
- Return on Assets -8%
- Return on Equity -36%
- Revenue 152.97 million
- Earnings Per Share $6.13
- Revenue Per Share $18.92
- Gross Profit 96.79 million
- Quarterly Earnings Growth -24.4%
Highlights
- Market Capitalization 52 million
- EBITDA -16363000
- PE Ratio -7.36
- PEG Ratio 0.51
- Analyst Target Price $17.5
- Book Value Per Share $25.13
Share Statistics
- Shares Outstanding 9.49 million
- Shares Float 8.46 million
- % Held by Insiders 169%
- % Held by Institutions 49.59%
- Shares Short 761102
- Shares Short Prior Month 750157
- Short Ratio 2.12
- Short % of Float 9%
- Short % of Shares Outstanding 8%
Technicals
- Beta 0.56
- 52 Week High $8.66
- 52 Week Low $2.53
- 50 Day Moving Average 6.55
- 200 Day Moving Average 5
Dividends
- Dividend Date 2021-01-04
- ExDividend Date N/A
- Dividend Yield 0%
Acorda Therapeutics, Inc (ACOR) Dividend Calendar:
ACOR's last dividend payment was made to shareholders on January 4, 2021.
Acorda Therapeutics, Inc (ACOR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Acorda Therapeutics, Inc (ACOR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Acorda Therapeutics, Inc (ACOR) Chart:
Acorda Therapeutics, Inc (ACOR) News:
Below you will find a list of latest news for Acorda Therapeutics, Inc (ACOR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Acorda Therapeutics, Inc (ACOR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ACOR Trades:
Acorda Therapeutics, Inc (ACOR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-03 | 8-K (Current report) | |
| 2020-10-19 | 8-K (Current report) | |
| 2020-10-05 | 8-K (Current report) | |
| 2020-09-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-18 | UPLOAD (SEC-generated letter) | |
| 2020-09-17 | 424B4 (Prospectus [Rule 424(b)(4)]) | |
| 2020-09-17 | EFFECT (Notice of Effectiveness) | |
| 2020-09-17 | EFFECT (Notice of Effectiveness) | |
| 2020-09-16 | UPLOAD (SEC-generated letter) | |
| 2020-09-16 | CORRESP (Correspondence) | |
| 2020-09-16 | CORRESP (Correspondence) | |
| 2020-09-11 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-09-11 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-08-31 | 8-K (Current report) | |
| 2020-08-28 | 8-K (Current report) | |
| 2020-08-20 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
Acorda Therapeutics, Inc (ACOR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Acorda Therapeutics, Inc (ACOR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 169%
Institutional Ownership: 4959%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-17 | Lauren M Sabella | Chief Commercial Officer | Buy | 3,015.00 | 15,639.00 | | ||
| 2020-09-17 | DAVID LAWRENCE | Chief, Bus. Ops & PAO | Buy | 3,015.00 | 15,976.00 | | ||
| 2020-09-17 | BURKHARD BLANK | CMO and Head of R&D | Buy | 3,015.00 | 44,410.00 | | ||
| 2020-09-17 | RON COHEN | President and CEO | Buy | 8,543.00 | 640,980.00 | | ||
| 2019-12-02 | Jane Wasman | President, Intl and GC | Sell | 2,227.00 | 1.60 | 3,552.73 | 117,420.00 | |
| 2019-12-02 | Lauren M Sabella | Chief Commercial Officer | Sell | 1,513.00 | 1.60 | 2,421.10 | 12,624.00 | |
| 2019-12-02 | DAVID LAWRENCE | Chief, Bus. Ops & PAO | Sell | 1,176.00 | 1.60 | 1,879.95 | 12,961.00 | |
| 2019-12-02 | RON COHEN | President and CEO | Sell | 4,699.00 | 1.60 | 7,505.24 | 607,287.00 | |
| 2019-03-08 | Jane Wasman | President, Intl and GC | Buy | 12,813.00 | 119,647.00 | | ||
| 2019-03-08 | DAVID LAWRENCE | Chief, Bus. Ops & PAO | Buy | 9,045.00 | 14,137.00 | | ||
| 2019-03-08 | Lauren M Sabella | Chief Commercial Officer | Buy | 9,045.00 | 14,137.00 | | ||
| 2019-03-08 | Andrew A. Hindman | Chief Business Officer | Buy | 9,045.00 | 15,639.00 | | ||
| 2019-03-08 | BURKHARD BLANK | CMO and Head of R&D | Buy | 9,045.00 | 41,395.00 | | ||
| 2019-03-08 | RON COHEN | President and CEO | Buy | 25,629.00 | 517,136.00 | | ||
| 2019-02-22 | DAVID LAWRENCE | Chief, Bus. Ops & PAO | Sell | 761.00 | 13.18 | 10,028.31 | 5,092.00 | |
| 2019-02-22 | Lauren M Sabella | Chief Commercial Officer | Sell | 761.00 | 13.18 | 10,028.23 | 5,092.00 | |
| 2019-01-30 | CAPITAL MANAGEMENT LP SCOPIA | 10% Share Holder | Sell | 7,000.00 | 16.01 | 112,039.20 | 4,750,219.00 | |
| 2019-01-25 | CAPITAL MANAGEMENT LP SCOPIA | 10% Share Holder | Sell | 2,401.00 | 16.00 | 38,416.00 | 4,757,219.00 | |
| 2019-01-24 | CAPITAL MANAGEMENT LP SCOPIA | 10% Share Holder | Sell | 8,600.00 | 16.03 | 137,851.12 | 4,759,620.00 | |
| 2019-01-23 | CAPITAL MANAGEMENT LP SCOPIA | 10% Share Holder | Sell | 45,898.00 | 16.01 | 734,941.73 | 4,768,220.00 | |